or Try an Advanced Search...

    Technical Analysis for NVCT - Nuvectis Pharma, Inc.

    Grade Last Price % Change Price Change
    D 5.07 -1.36% -0.07
    NVCT closed down 1.36 percent on Wednesday, November 20, 2024, on 79 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Strong Down Down Down
    Historical NVCT trend table...
    Date Alert Name Type % Chg
    Calm After Storm Range Contraction 0.00%
    Narrow Range Bar Range Contraction 0.00%
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Oversold Stochastic Weakness 0.00%
    Calm After Storm Range Contraction -1.36%
    New 52 Week Low Weakness -1.36%
    Outside Day Range Expansion -1.36%
    Wide Bands Range Expansion -1.36%
    Oversold Stochastic Weakness -1.36%
    Older End-of-Day Signals for NVCT ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 18 hours ago
    Down 3% about 18 hours ago
    Up 3% about 18 hours ago
    Down 2 % about 18 hours ago
    Down 1% about 18 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Get Started for Free!
    Configure default chart indicators
    NVCT Chart by TradingView
    Basic chart:

    Profile

    Nuvectis Pharma, Inc., a biopharmaceutical company, focuses on the development of targeted small molecule therapeutics for the treatment of cancer. The company develops NXP800, an oral small molecule inhibitor of the Heat Shock Factor 1 pathway, a signaling pathway in the initiation and progression of various cancers; and NXP900 program, an oral small molecule designed to inhibit the SRC and YES1 kinases. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biopharmaceutical Cancer Life Sciences Biology Treatment Of Cancer Tyrosine Kinase Oncogenes Cancer Research Small Molecule Kinase Proto Oncogene Tyrosine Protein Kinase Src

    Is NVCT a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Nov 15 Nuvectis Pharma reports data from Phase 1b study of NXP800
    Nov 14 Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
    Nov 14 Nuvectis sinks after early-stage data for ovarian cancer therapy
    Nov 14 Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resistant ARID1a-Mutated Ovarian Cancer
    Nov 13 Nuvectis Pharma (NVCT) Is a Great Choice for 'Trend' Investors, Here's Why
    Nov 5 Nuvectis Pharma GAAP EPS of -$0.24 beats by $0.01
    Nov 5 Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
    Oct 28 PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
    Oct 7 Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
    Sep 16 PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
    See more NVCT news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 12.1
    52 Week Low 4.75
    Average Volume 195,549
    200-Day Moving Average 7.17
    50-Day Moving Average 7.04
    20-Day Moving Average 7.72
    10-Day Moving Average 7.75
    Average True Range 1.18
    RSI (14) 36.31
    ADX 27.2
    +DI 20.61
    -DI 30.94
    Chandelier Exit (Long, 3 ATRs) 8.26
    Chandelier Exit (Short, 3 ATRs) 8.29
    Upper Bollinger Bands 11.66
    Lower Bollinger Band 3.78
    Percent B (%b) 0.16
    BandWidth 102.01
    MACD Line -0.37
    MACD Signal Line 0.15
    MACD Histogram -0.5182
    Fundamentals Value
    Market Cap 87.85 Million
    Num Shares 17.3 Million
    EPS -1.50
    Price-to-Earnings (P/E) Ratio -3.38
    Price-to-Sales 0.00
    Price-to-Book 7.15
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 5.90
    Resistance 3 (R3) 5.90 5.63 5.76
    Resistance 2 (R2) 5.63 5.42 5.63 5.71
    Resistance 1 (R1) 5.35 5.29 5.22 5.35 5.67
    Pivot Point 5.08 5.08 5.01 5.08 5.08
    Support 1 (S1) 4.80 4.87 4.67 4.80 4.47
    Support 2 (S2) 4.53 4.74 4.53 4.43
    Support 3 (S3) 4.25 4.53 4.38
    Support 4 (S4) 4.25